Abstral (Rapinyl) Receives Positive CHMP Opinion For Breakthrough Cancer Pain - Europe ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMEA) has issued a positive opinion recommending approval of Abstral (formerly branded as Rapinyl), the fast-acting tablet for breakthrough cancer pain. ProStrakan plans to launch Abstral in Sweden in Q3 2008 and, as a result of today's announcement, across Europe from the end of 2008.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
